The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 11 July 2006, www.theannals.com, DOI 10.1345/aph.1H005.
 The Annals of Pharmacotherapy: Vol. 40, No. 7, pp. 1388-1393. DOI 10.1345/aph.1H005
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levien, T. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levien, T. L

DRUG INFORMATION ROUNDS

Phosphodiesterase Inhibitors in Raynaud's Phenomenon

Terri L Levien, PharmD

Drug Information Pharmacist and Clinical Assistant Professor, Pharmacotherapy Department, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, WA 99210-1495, fax 509/358-7744, Levient{at}wsu.edu

Reprints: Dr. Levien

OBJECTIVE: To evaluate the efficacy of the phosphodiesterase type 5 (PDE5) inhibitors in the treatment of Raynaud's phenomenon.

DATA SOURCES: Searches of MEDLINE (1966-March 2006) and Web of Science (1980-March 2006) were conducted; search terms were sildenafil, tadalafil, vardenafil, phosphodiesterase, and Raynaud. Studies and case reports published in English were retrieved. Additional references were identified in bibliographic reviews.

DATA SYNTHESIS: Several small studies and a number of case reports have described the use of PDE5 inhibitors in patients with either primary or secondary Raynaud's phenomenon. The data from the best designed study show a reduced attack frequency and duration, reduced Raynaud Condition Score, and increased capillary blood flow in patients with secondary Raynaud's phenomenon.

CONCLUSIONS: Available evidence suggests that sildenafil may be associated with improved microcirculation, symptomatic relief, and ulcer healing in patients with secondary Raynaud's phenomenon. Limited information suggests similar effects with tadalafil and vardenafil. Improved blood flow and clinical improvements have also been observed in some patients with primary Raynaud's phenomenon treated with PDE5 inhibitors; however, studies have yielded conflicting results.

Key Words: Raynaud's phenomenon, sildenafil, tadalafil, vardenafil

Published Online, July 11, 2006. www.theannals.com, DOI 10.1345/aph.1H005


This article has been cited by other articles:


Home page
 J AndrolHome page
A. L. Burnett
Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health
J Androl, January 1, 2008; 29(1): 3 - 14.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Colakoglu, V. Cobankara, and T. Akpolat
Effect of Clonazepam on Raynaud's Phenomenon and Fingertip Ulcers in Scleroderma
Ann. Pharmacother., September 1, 2007; 41(9): 1544 - 1547.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.